Published in Pharmaceutical Technology, 43 (10) 2019.
As the development pipeline becomes more saturated with complex molecules and patient experience becomes more important, developers are looking to outsourcing partners to provide more specialized expertise and solutions. Oral-solid dosage forms remain the most common drug formulation used within the pharmaceutical industry and, according to market research, should continue to experience market growth in the near future. However, a range of factors, such as an amassing focus on biologics, higher proportion of poorly soluble molecules in the development pipeline, and regulatory development pathways, are potentially set to shift the balance and raise the profile of newer, innovative dosage forms, increasing the requirement for expert skills.
In this article, Dr. Robert Lee, President of the CDMO Division of LLS Health, joins other industry experts to address:
- Overcoming bioavailability issues
- Accelerated regulatory approval pathways
- Patient-centric design approaches
- Areas of growth